Novavax (NVAX 2.06%) shares soared more than 2,000% last year. But that doesn't mean share performance is over. In this Motley Fool Live video recorded on June 22, 2021, healthcare and cannabis bureau editor and analyst Olivia Zitkus and Fool.com contributor Adria Cimino discuss catalysts that may lift the shares in the coming months and years.
10 stocks we like better than Novavax
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Novavax wasn't one of them! That's right -- they think these 10 stocks are even better buys.
*Stock Advisor returns as of June 7, 2021
Olivia Zitkus: I wanted to ask you what you thought about where Novavax is trading right now. It had a crazy 2020, absolutely insane. So far this year, I think it's up more than 60%. Do you think it has more room to grow? What do you think?
Adria Cimino: I think so, I really do. I think that there's a lot more potential. They have orders from various countries, they ramped up the production, infrastructure, and this is just a good way to continue. Now we're on the possibility of revenue ahead, the combined flu and COVID vaccine down the road. These are all things that can lead to share gains. Of course, it might not gain 2,000% in one year like it did last year, but that's OK. I think that still there's potential ahead.
